UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting

The New England journal of medicine, 2016-04, Vol.374 (14), p.1356-1367

2016

Volltextzugriff (PDF)

Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting

European journal of pharmacology, 2014-01, Vol.722, p.180-186

Navari, Rudolph M.

2014

Volltextzugriff (PDF)

Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting

The New England journal of medicine, 2016-07, Vol.375 (2), p.134-142

2016

Volltextzugriff (PDF)

Treatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and Vomiting

BioMed research international, 2015-01, Vol.2015 (2015), p.1-6

2015

Volltextzugriff (PDF)

The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy

Supportive care in cancer, 2013-06, Vol.21 (6), p.1655-1663

2013

Volltextzugriff (PDF)

Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial

The lancet oncology, 2015-09, Vol.16 (9), p.1071-1078

2015

Volltextzugriff (PDF)

2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting

Supportive care in cancer, 2017-01, Vol.25 (1), p.303-308

2017

Volltextzugriff (PDF)

Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials

The lancet oncology, 2015-09, Vol.16 (9), p.1079-1089

2015

Volltextzugriff (PDF)

Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial

The Journal of supportive oncology, 2011-09, Vol.9 (5), p.188-195

2011

Volltextzugriff (PDF)

Olanzapine 5 mg vs 10 mg for the prophylaxis of chemotherapy-induced nausea and vomiting: a network meta-analysis

Supportive care in cancer, 2022-02, Vol.30 (2), p.1015-1018

2022

Volltextzugriff (PDF)

Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis

Supportive care in cancer, 2016-05, Vol.24 (5), p.2381-2392

2016

Volltextzugriff (PDF)

Management of Chemotherapy-Induced Nausea and Vomiting: Focus on Newer Agents and New Uses for Older Agents

Drugs (New York, N.Y.), 2013-03, Vol.73 (3), p.249-262

Navari, Rudolph M.

2013

Volltextzugriff (PDF)

5-HT3 receptors as important mediators of nausea and vomiting due to chemotherapy

Biochimica et biophysica acta, 2015-10, Vol.1848 (10), p.2738-2746

Navari, Rudolph M.

2015

Volltextzugriff (PDF)

Safety of Polysorbate 80 in the Oncology Setting

Advances in therapy, 2018-06, Vol.35 (6), p.754-767

2018

Volltextzugriff (PDF)

Nausea and Vomiting in Advanced Cancer

Current treatment options in oncology, 2020-02, Vol.21 (2), p.14-14, Article 14

Navari, Rudolph M.

2020

Volltextzugriff (PDF)

Management of Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients

Paediatric drugs, 2017-06, Vol.19 (3), p.213-222

Navari, Rudolph M.

2017

Volltextzugriff (PDF)

Management of Chemotherapy-Induced Nausea and Vomiting: New Agents and New Uses of Current Agents

1st ed. 2016, 2016

Volltextzugriff (PDF)

Antiemetic control: toward a new standard of care for emetogenic chemotherapy

Expert opinion on pharmacotherapy, 2009-03, Vol.10 (4), p.629-644

Navari, Rudolph M

2009

Volltextzugriff (PDF)

Safety profile of HTX-019 administered as an intravenous push in cancer patients: a retrospective review

Expert opinion on drug safety, 2020-02, Vol.19 (2), p.205-210

Navari, Rudolph M

2020

Volltextzugriff (PDF)

The safety of antiemetic medications for the prevention of chemotherapy-induced nausea and vomiting

Expert opinion on drug safety, 2016-03, Vol.15 (3), p.343-356

Navari, Rudolph M.

2016

Volltextzugriff (PDF)

Prevention of emesis from multiple-day and high-dose chemotherapy regimens

Journal of the National Comprehensive Cancer Network, 2007-01, Vol.5 (1), p.51-59

Navari, Rudolph M

2007

Volltextzugriff (PDF)

Managing Nausea and Vomiting in Patients With Cancer: What Works

Oncology (Williston Park, N.Y.), 2018-03, Vol.32 (3), p.121-136

Navari, Rudolph M

2018

Volltextzugriff (PDF)

Selective photocrosslinking of functional ligands to antibodies via the conserved nucleotide binding site

Biomaterials, 2013-07, Vol.34 (22), p.5700-5710

2013

Volltextzugriff (PDF)

A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study

Supportive care in cancer, 2007-11, Vol.15 (11), p.1285-1285, Article 1285

2007

Volltextzugriff (PDF)

The safety of rolapitant for the treatment of nausea and vomiting associated with chemotherapy

Expert opinion on drug safety, 2019-12, Vol.18 (12), p.1127-1132

Navari, Rudolph M

2019

Volltextzugriff (PDF)

1 – 25 von 183

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(153)
Mit Volltextzugriff
(144)

Publikationsform

Artikel
(164)
Buchkapitel
(18)
Bücher
(1)

Sprache

Englisch
(183)

Erscheinungsjahr

n.n

Thema

Science & Technology
(93)
Life Sciences & Biomedicine
(90)
Humans
(83)
Oncology
(75)
Nausea - Chemically Induced
(53)
Vomiting - Chemically Induced
(53)
Nausea
(45)
Chemotherapy
(43)
Antiemetics - Therapeutic Use
(41)
Antineoplastic Agents - Adverse Effects
(40)
Vomiting - Prevention & Control
(39)
Vomiting
(38)
Nausea - Prevention & Control
(36)
Female
(35)
Middle Aged
(34)
Antiemetics
(32)
Male
(32)
Adult
(30)
Aged
(29)
Nausea - Drug Therapy
(27)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting

Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting

Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting

Treatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and Vomiting

The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy

Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial

2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting

Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials

Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial

Olanzapine 5 mg vs 10 mg for the prophylaxis of chemotherapy-induced nausea and vomiting: a network meta-analysis

Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis

Management of Chemotherapy-Induced Nausea and Vomiting: Focus on Newer Agents and New Uses for Older Agents

5-HT3 receptors as important mediators of nausea and vomiting due to chemotherapy

Safety of Polysorbate 80 in the Oncology Setting

Nausea and Vomiting in Advanced Cancer

Management of Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients

Management of Chemotherapy-Induced Nausea and Vomiting: New Agents and New Uses of Current Agents

Antiemetic control: toward a new standard of care for emetogenic chemotherapy

Safety profile of HTX-019 administered as an intravenous push in cancer patients: a retrospective review

The safety of antiemetic medications for the prevention of chemotherapy-induced nausea and vomiting

Prevention of emesis from multiple-day and high-dose chemotherapy regimens

Managing Nausea and Vomiting in Patients With Cancer: What Works

Selective photocrosslinking of functional ligands to antibodies via the conserved nucleotide binding site

A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study

The safety of rolapitant for the treatment of nausea and vomiting associated with chemotherapy

Suchergebnisse filtern